Objective: To describe and compare infants with severe hyperbilirubinemia, who presented with and without abnormal neurological findings and to identify associated risk factors. ) and lowest level (p450 mmol l À1 ) groups were less likely to have abnormalities (odds ratio (OR) ¼ 0.174; P ¼ 0.0013 and 0.402; P ¼ 0.0613, respectively). Exchange transfusion and presentation within the first 2 days of age were positively associated with abnormal neurological findings in infants (OR ¼ 3.332, P ¼ 0.003 and OR ¼ 2.572, P<0.0001, respectively).
Introduction
Neonatal hyperbilirubinemia remains the most common cause of readmission in the neonatal period, despite attempts to identify at-risk newborns for severe hyperbilirubinemia before initial discharge from the hospital. [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] Long-term sequelae of severe hyperbilirubinemia, including bilirubin encephalopathy and kernicterus, were thought to be rare since the advent of maternal rhesus immunoglobulin prophylaxis, phototherapy and exchange transfusions. [11] [12] [13] However, cases of bilirubin encephalopathy and kernicterus continue to be reported in healthy near-term and term infants in North America and Europe. 1,11 -20 We recently reported on 258 infants with severe hyperbilirubinemia in Canada from 2002 to 2004 through the CPSP. 10 The most common identifiable etiology of severe hyperbilirubinemia in our cohort was ABO incompatibility followed by glucose-6-phosphate dehydrogenase deficiency, with many infants presenting with abnormal neurological symptoms and signs on admission.
Acute bilirubin encephalopathy occurs when bilirubin levels become neurotoxic in infants. 9, 12 Three phases of acute bilirubin encephalopathy have been described. The early acute phase is characterized by lethargy, hypotonia and poor suck; intermediate phase by hypertonia (including opisthotonus and retrocollis), high-pitched cry, fever, moderate stupor or irritability, whereas in the advanced phase infants present with seizures, coma, apnea, pronounced retrocollis and opisthotonus, with death occurring in severe cases. 9, 12 Although the acute neurological abnormalities of hyperbilirubinemic infants can be transient, the intermediate and advanced phases have been strongly linked to long-term neurological sequelae. 21 The inability of physicians to recognize bilirubin encephalopathy early may lead to delays in treatment, thereby increasing the risk of long-term sequelae. 22 The objective of this study was to describe and compare the clinical course of infants with and without abnormal neurological findings on admission to identify and better refine risk factors associated with the occurrence of acute neurological findings.
Methods
Subjects were identified from a previously reported national database on infants with severe hyperbilirubinemia (>425 mmol l À1 and/or received exchange transfusion) through the CPSP for the period July 2002 to June 2004. 10 The methodology that was utilized to obtain data has been previously described. 10 The protocol and questionnaire were reviewed and approved by the CPSP Steering Committee panel of experts, and by the Research Ethics Boards of two hospitals (St Michael's Hospital and Mount Sinai Hospital, Toronto, ON). A subsequent protocol was reviewed and approved by the Research Ethics Boards of both institutions for this secondary analysis.
Cases in which the reporting physician identified neurological abnormalities in the neonatal period were identified and compared with those without neurological abnormalities. Acute neurological abnormalities were defined as infants having a clinical syndrome consistent with acute bilirubin encephalopathy (early, intermediate or advanced). 11, 12 These include seizures, hypertonia, hypotonia, irritability, apnea, retrocollis, opisthotonus and poor suck. 11, 12 Data on demographic characteristics, clinical course and management were collected on a standardized data collection form. 10 Data were summarized using descriptive statistics for baseline characteristics. To compare babies with and without abnormalities and normal infants, the w 2 test was used and the non-parametric, Wilcoxon test was used for continuous variables. Univariate logistic regression analysis was performed to evaluate the effect of predictors (age of infant presentation, peak serum bilirubin, need for readmission, etiology of hyperbilirubinemia and need for exchange transfusion) on neurological abnormities. The final results are reported as OR along with their 95% confidence intervals. Owing to missing data in the predictors and the low number of cases (N ¼ 32), we did not attempt to conduct multivariate analyses. The age of presentation was categorized as p2 days of age and >2 days of age. This time point was chosen as those with severe hyperbilirubinemia presenting early are likely to have hemolytic disease. Peak serum bilirubin was categorized as: p450 mmol l À1 , 451 to 550 mmol l À1 and >550 mmol l
À1
, as these levels of hyperbilirubinemia have previously been linked to abnormal outcomes. The significance level was set at P<0.05. Statistical analysis was performed using the statistical software package SAS version 9.2 (SAS Institute, Cary, NC, USA).
Results
The initial cohort consisted of data on 258 infants with severe hyperbilirubinemia, of which 52 were reported to have some degree of neurological abnormalities. 10 A total of 20 of these infants had non-specific neurological findings: either isolated irritability (N ¼ 8) or poor feeding (N ¼ 12), and were not considered to have enough symptoms to be included with confidence. 11, 12 In all, 32 infants therefore had neurological abnormalities consistent with acute bilirubin encephalopathy. 12 Six of these infants had intermediate or advanced bilirubin encephalopathy with seizures and/or opisthotonus during the initial presentation.
The baseline characteristics of the two cohorts (neonates with and without abnormal neurological findings) were similar ( Table 1 ). The clinical presentation of the 32 infants with acute neurological abnormalities is presented in In all, 13 (41%) of the 32 infants with neurological findings had an identifiable etiology established for the hyperbilirubinemia (Table 2) . A total of 80 (35%) of the 226 infants without neurological findings had a diagnosis established for the hyperbilirubinemia. Exchange transfusions were performed in 14 (44%) of the 32 neonates with neurological abnormalities and 43 (19%) of the 226 infants without abnormalities, respectively. All were treated with phototherapy.
Univariate logistic regression analysis identified that infants in the highest peak bilirubin level group (>550 mmol l À1 ) had the greatest risk of acute neurological abnormalities (9/27 or 30%). The mid range (451 to 550 mmol l
À1
) group had a lower rate of neurological abnormalities (9/132 or 6.8%) OR of 0.174 (P ¼ 0.0013). The lowest bilirubin level group (p450 mmol l À1 ) had 15 babies who were abnormal (15/99 or 15%) with an OR of 0.402 (P ¼ 0.0613). Need for exchange transfusion and presentation at p2 days of age was also associated with a higher risk of acute neurological findings (Table 3) . 
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Discussion
Our study highlights the association between severe neonatal hyperbilirubinemia and acute bilirubin encephalopathy. In our cohort, the presence of acute neurological findings correlated with higher peak bilirubin, the need for exchange transfusion and an early age of presentation (first 2 days of life). The trend to more neurological abnormalities in the lower bilirubin level group (<450 mmol l À1 ) compared with the mid-range group (450 to 550 mmol l À1 ) is likely related to the fact that early presentation and therefore a rapid rise in serum bilirubin levels increases the risk of acute bilirubin encephalopathy even at lower serum bilirubin levels 23 (Table 3) . These data may help to explain previous studies that have failed to show a strong correlation between serum bilirubin levels and kernicterus. 6, 9, 11, 13, 14 In our cohort, early presentation (<2 days) was a significant risk factor, and this group's mean peak serum bilirubin levels were lower than that of the older newborns.
We were unable to demonstrate a relationship between etiology and the likelihood of acute bilirubin encephalopathy. Previous studies have shown that both acute bilirubin encephalopathy and kernicterus were more likely to occur if the hyperbilirubinemia was secondary to hemolysis and a specific etiology, such as glucose-6-phosphate dehydrogenase deficiency or ABO incompatibility. 1, 11, 16 It is possible that the reason we were unable to show a relationship in our study was the low rate of reported etiology for the hyperbilirubinemia. This limitation was difficult to avoid because of the fact that we were relying on voluntary reporting; many infants with an 'unknown etiology' may not have been completely investigated.
The incidence of acute bilirubin encephalopathy is unknown, but is thought to be rare. 22, 24 The Canadian birth rate was B330 000 infants per year at the time of our study. 25 Our data therefore suggest an incidence of acute bilirubin encephalopathy of B1 in 20 000 live births. It is likely that the infants excluded from our initial analysis with 'non-specific findings' (isolated irritability (N ¼ 8) and poor feeding (N ¼ 12)) also had early acute bilirubin encephalopathy, given the very high bilirubin levels necessary to be entered into the database (>425 mmol l À1 ). 10, 12 If these infants were included, the incidence of acute bilirubin encephalopathy would be B1/10 000 live births. This estimate is in keeping with two national cohorts reported from Denmark in 2000-2001 and 2002-2005. 26,27 A recent study from the United Kingdom reported a much lower incidence of 0.9/100 000 live births. 16 In this study however, only infants with peak serum bilirubin levels of >510 mmol l À1 were included. 16 Six infants in our study had intermediate and/or advanced signs of encephalopathy corresponding to a incidence of 1.8/100 000. This is higher than what has previously been reported by the British and Danish groups. 16, 26, 27 The occurrence of acute bilirubin encephalopathy may not translate into permanent neurological sequelae, but is concerning nonetheless. 20, 28 Of the 14 infants with acute bilirubin encephalopathy evaluated at 12 months in the study by Manning et al., 16 7 had significant adverse neurological outcomes (including cerebral palsy), 3 died, whereas 3 were normal and 1 was lost to follow-up. We would suggest that all infants with peak bilirubin levels >425 mmol l À1 be followed long-term as part of neonatal follow-up programs.
The main limitation of our study is related to information collected via a voluntary reporting system. We were neither able to corroborate the acute abnormal neurological findings nor could we report on whether all of these infants had permanent sequelae on follow-up. We tried to account for this by only including infants who had significantly abnormal neurological features, for example, hypotonia and abnormal auditory evoked responses. It is likely that the voluntary reporting system underestimates the true incidence of acute bilirubin encephalopathy, as not all cases may have been captured, and reported cases were not completely described.
Conclusion
Our study had a significant number of infants with neurological findings secondary to acute bilirubin encephalopathy, putting them at significant risk of adverse long-term neurological outcomes. We feel that physician recognition of the clinical syndrome of acute bilirubin encephalopathy is of utmost importance. When these symptoms present, aggressive treatment of the acute neonatal hyperbilirubinemia is urgently required.
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